Risk/Benefit Assessment of β-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
S ystemic arterial hypertension affects 72 million US adults and an additional hundreds of millions of persons worldwide.1,2 Most of these are candidates for pharmacological treatment to reduce risk of cardiovascular disease (CVD) events, based primarily on a very large body of epidemiological and intervention research in humans.Because of this high prevalence and the cardiovascular consequences of untreated or inadequately treated hypertension, the selection of drugs for initial and continuing, long-term treatment has large public health and economic implications.Fortunately, such decisions and the expert recommendations that seek to guide them can call on evidence from 4 decades of randomized multicenter clinical trials evaluating effects of treatment on clinical CVD.We summarize that evidence in this article, in approximate chronological order, and we comment on the related treatment guidelines.We close with some of the major clinical questions yet to be resolved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2981 · Cited by 5,664
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus
Gress, T. W., Nieto, F. J., Shahar, E., Wofford, M. R., & Brancati, F. L. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003303421301 · Cited by 1,202
Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis
Elliott, W. J., & Meyer, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60108-1 · Cited by 1,016
Adverse Prognostic Significance of New Diabetes in Treated Hypertensive Subjects
Verdecchia, P., Reboldi, G., Angeli, F., Borgioni, C., Gattobigio, R., Filippucci, L., Norgiolini, S., Bracco, C., & Porcellati, C. (2004) · Hypertension · doi:10.1161/01.hyp.0000125726.92964.ab · Cited by 510
(1977) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1977.03270300059008 · Cited by 334
Kostis, J. B., Wilson, A. C., Freudenberger, R. S., Cosgrove, N. M., Pressel, S. L., & Davis, B. R. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.059 · Cited by 325
Cited by
Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328333146d · Cited by 1,643
Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Blood Pressure · doi:10.3109/08037050903450468 · Cited by 894
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
Evidence-based Diuretics: Focus On Chlorthalidone and Indapamide
DiNicolantonio, J. J., Bhutani, J., Lavie, C. J., & O’Keefe, J. H. (2015) · Future Cardiology · doi:10.2217/fca.14.83 · Cited by 29
Metadata
- Authors
- Messerli, F. H., Bangalore, S., & Julius, S.
- Venue
- Circulation
- Published
- 2008-05-20
- Volume
- 117
- Issue
- 20
- Pages
- 2706-2715
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2130513215
- Cited by
- 132
- References
- 7
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.